Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use.
(2015) In Osteoarthritis and Cartilage 23(8). p.1233-1241- Abstract
- Osteoarthritis (OA) is a heterogeneous disorder. The goals of this review are (1) To stimulate use of standardized nomenclature for OA that could serve as building blocks for describing OA and defining OA phenotypes, in short to provide unifying disease concepts for a heterogeneous disorder; and (2) To stimulate establishment of ROAD (Risk of OA Development) and ROAP (Risk of OA Progression) tools analogous to the FRAX™ instrument for predicting risk of fracture in osteoporosis; and (3) To stimulate formulation of tools for identifying disease in its early preradiographic and/or molecular stages - REDI (Reliable Early Disease Identification). Consensus around more sensitive and specific diagnostic criteria for OA could spur development of... (More)
- Osteoarthritis (OA) is a heterogeneous disorder. The goals of this review are (1) To stimulate use of standardized nomenclature for OA that could serve as building blocks for describing OA and defining OA phenotypes, in short to provide unifying disease concepts for a heterogeneous disorder; and (2) To stimulate establishment of ROAD (Risk of OA Development) and ROAP (Risk of OA Progression) tools analogous to the FRAX™ instrument for predicting risk of fracture in osteoporosis; and (3) To stimulate formulation of tools for identifying disease in its early preradiographic and/or molecular stages - REDI (Reliable Early Disease Identification). Consensus around more sensitive and specific diagnostic criteria for OA could spur development of disease modifying therapies for this entity that has proved so recalcitrant to date. We fully acknowledge that as we move forward, we expect to develop more sophisticated definitions, terminology and tools. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/5342072
- author
- Kraus, V B ; Blanco, F J ; Englund, Martin LU ; Karsdal, M A and Lohmander, Stefan LU
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Osteoarthritis and Cartilage
- volume
- 23
- issue
- 8
- pages
- 1233 - 1241
- publisher
- Elsevier
- external identifiers
-
- pmid:25865392
- wos:000358434600002
- scopus:84938216409
- pmid:25865392
- ISSN
- 1063-4584
- DOI
- 10.1016/j.joca.2015.03.036
- language
- English
- LU publication?
- yes
- id
- a4293fce-6178-4df7-b695-3677f9247f02 (old id 5342072)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/25865392?dopt=Abstract
- date added to LUP
- 2016-04-01 10:41:12
- date last changed
- 2023-03-09 00:50:04
@article{a4293fce-6178-4df7-b695-3677f9247f02, abstract = {{Osteoarthritis (OA) is a heterogeneous disorder. The goals of this review are (1) To stimulate use of standardized nomenclature for OA that could serve as building blocks for describing OA and defining OA phenotypes, in short to provide unifying disease concepts for a heterogeneous disorder; and (2) To stimulate establishment of ROAD (Risk of OA Development) and ROAP (Risk of OA Progression) tools analogous to the FRAX™ instrument for predicting risk of fracture in osteoporosis; and (3) To stimulate formulation of tools for identifying disease in its early preradiographic and/or molecular stages - REDI (Reliable Early Disease Identification). Consensus around more sensitive and specific diagnostic criteria for OA could spur development of disease modifying therapies for this entity that has proved so recalcitrant to date. We fully acknowledge that as we move forward, we expect to develop more sophisticated definitions, terminology and tools.}}, author = {{Kraus, V B and Blanco, F J and Englund, Martin and Karsdal, M A and Lohmander, Stefan}}, issn = {{1063-4584}}, language = {{eng}}, number = {{8}}, pages = {{1233--1241}}, publisher = {{Elsevier}}, series = {{Osteoarthritis and Cartilage}}, title = {{Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use.}}, url = {{https://lup.lub.lu.se/search/files/2052933/8260323.pdf}}, doi = {{10.1016/j.joca.2015.03.036}}, volume = {{23}}, year = {{2015}}, }